Top 5 Biotechnology Startup Investors in Isle of Man in September 2025
A list of 5 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups based in Isle of man. We rank investors based on the number of investments they made in Biotechnology companies from Isle of man. We update this investor list every month.Top 5 Biotechnology Startup Investors in Isle of Man in September 2025
Investor | Biotechnology Isle of Man investments |
---|---|
Juvenescence | 1 |
Andrew Banks | 1 |
Jim Mellon | 1 |
Foresite Capital | 1 |
Greg Bailey | 1 |
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Funding Round, Series A, Debt Financing
- United States, Hong Kong, Isle of Man
Portfolio highlights
- LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
- MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
- Souvien Therapeutics — Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
Andrew Banks - Chairman and Co-Founder @ ABRY Partners
Show more
Investment focus
- Biopharma, Biotechnology, Pharmaceutical
- Seed
- Isle of Man
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more
Investment focus
- Biotechnology, Food and Beverage, Health Care
- Series A, Seed, Funding Round
- United States, United Kingdom, Germany
Portfolio highlights
- Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Medical
- Series A, Seed, Funding Round
- United States, Isle of Man
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
- Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
- Biohaven Pharmaceutical — Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Investors by industry
Google
Marketplace
Hardware
Energy
Proptech
Health Care
Biotech
Artificial intelligence
Climate
Consumer
Community
Impact
Gaming
FinTech
EdTech
Sustainability
Venture Capital
Big Data
Web3
B2B
Financial Services
Finance
Infrastructure
Education
Photography
Payments
Food and Beverage
Video Games
Organic Food
Retail
Beauty
Manufacturing
Art
Music
Android
Internet
Enterprise Software
eSports
Franchise
Sports
Construction
Digital Media
Email
Medical
Social Network
Wellness
Social Media
Mobile
Legal
Local
Recruiting
Cannabis
Platforms
Fitness
Travel
Mobile Advertising
Biotechnology
Hospitality
Social
Automotive
Crowdfunding
Wine And Spirits
Medical Device
CleanTech
Publishing
Transportation
Mobile Apps
Clean Energy
InsurTech
Enterprise
Real Estate
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Sporting Goods
Renewable Energy
SaaS
Restaurants
Software
Celebrity
Social Impact
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Canada
South Korea
Ireland
United States
New Zealand
India
Germany
Australia
Armenia
South Africa
Spain
Japan
Africa
China
Sri Lanka
Singapore
Qatar
Asia
Indonesia
Vietnam
Oceania
LATAM
Middle East
Europe
Saudi Arabia
Brazil
Bulgaria
Belize
Bahrain
Croatia
Georgia
Belarus
Hungary
France
Ghana
Ethiopia
Gibraltar
Chile
Egypt
Finland
Costa Rica
Liechtenstein
Greece
Liberia
Lebanon
Mauritius
Barbados
Belgium
Peru
Norway
Estonia
Israel
Malaysia
Mexico
Bermuda
Czech Republic
Nicaragua
Jersey
Panama
Denmark
Morocco
Mali
Algeria
Lithuania
Hong Kong
Italy
Philippines
Kuwait
Malta
Myanmar
Sierra Leone
El Salvador
Ecuador
Uganda
Venezuela
Faroe Islands
Dominican Republic
Azerbaijan
Sweden
Slovenia
Poland
Uruguay
Ukraine
Tajikistan
Puerto Rico
Iceland
Portugal
Tunisia
Taiwan
Tanzania
Turkey
San Marino
Senegal
Togo
Uzbekistan
Serbia
Russian Federation
Zambia
Nigeria
Rwanda
Zimbabwe
Thailand
Bahamas
United Arab Emirates
Jamaica
Namibia
Honduras
Iraq
Isle of Man
Luxembourg
Bolivia
Kazakhstan
Pakistan
Albania
Grenada
Jordan
Romania
Bangladesh
Argentina
Kenya
Cayman Islands
Cambodia
Austria
Oman
Latvia
Cyprus
Switzerland
Cameroon
Colombia
Guatemala
Seychelles
Marshall Islands
Investors in Isle of Man by industry